I'm LongbridgeAI, I can summarize articles.Kahn Swick & Foti, LLC reminds investors with losses exceeding $100,000 in Erasca, Inc. (ERAS) shares that the deadline to file lead plaintiff applications for a securities class action is August 10, 2026. The lawsuit alleges Erasca and executives violated federal securities laws by failing to disclose material information regarding preclinical data for its ERAS-0015 product between January 14, 2025, and April 26, 2026.
Erasca 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Erasca, Inc. - ERAS
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against Erasca, Inc. (“Erasca” or the “Company”) (NasdaqGS: ERAS), if they purchased or otherwise acquired the Company’s shares between January 14, 2025 and April 26, 2026, both dates inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of California.
What You May Do
If you purchased shares of Erasca as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 833-538-3615 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-eras/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by August 10, 2026.
About the Lawsuit
Erasca and certain of its executives are charged with failing to disclose material information during the class period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the preclinical data for the Company’s ERAS-0015 product, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors, was based on improper comparisons to Revolution Medicines, Inc. and placed Erasca at risk of violating patent and trade secret protections; and (ii) based on the foregoing, the defendants lacked a reasonable basis for their positive statements related to ERAS-0015.
The case is Cheng v. Erasca, Inc., No. 26-cv-03481.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
833-538-3615
1100 Poydras St., Suite 960
New Orleans, LA 70163
View source version on businesswire.com: https://www.businesswire.com/news/home/20260807929088/en/